STOCK TITAN
  1. Home
  2. Sec-filings
  3. VRCA
  4. [Form 4] Verrica Pharmaceuticals Inc. Insider Trading Activity

VRCA insider Form 4: Interim CFO stock and warrant purchase

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Interim CFO. On 11/25/2025, the executive bought 3,536 shares of common stock at $4.2425 per share, bringing their directly held common stock to 8,962 shares after the transaction.

The filing also reports acquisition of 884 Series C warrants with an exercise price of $6.315 per share, exercisable immediately until 11/25/2030, each warrant linked to common stock. All security amounts reflect a 1-for-10 reverse stock split effective July 24, 2025. The Series C warrants include a 9.99% beneficial ownership cap, limiting how many shares can be obtained through exercise relative to the company’s outstanding common stock.

Positive

  • None.

Negative

  • None.
Insider Kirby John J.
Role Interim CFO
Bought 4,420 shs ($15K)
Type Security Shares Price Value
Purchase Series C Warrant (right to buy) 884 $0.00 --
Purchase Common Stock 3,536 $4.2425 $15K
Holdings After Transaction: Series C Warrant (right to buy) — 884 shares (Direct); Common Stock — 8,962 shares (Direct)
Footnotes (1)
  1. Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. Immediately exercisable. The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kirby John J.
(Last) (First) (Middle)
C/O VERRICA PHARMACEUTICALS INC.
44 W. GAY ST., SUITE 400
(Street)
WEST CHESTER PA 19380
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Interim CFO
3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/25/2025 P 3,536 A $4.2425 8,962(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Warrant (right to buy) $6.315 11/25/2025 P 884 (2) 11/25/2030 Common Stock 884 (3) 884 D
Explanation of Responses:
1. Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
2. Immediately exercisable.
3. The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
/s/ John J. Kirby 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Verrica Pharmaceuticals (VRCA) report on this Form 4?

The Interim CFO of Verrica Pharmaceuticals Inc. (VRCA) reported buying 3,536 shares of common stock on 11/25/2025, as disclosed in this Form 4.

At what price did the Verrica (VRCA) Interim CFO purchase common stock?

The Interim CFO purchased 3,536 shares of Verrica common stock at a price of $4.2425 per share.

How many Verrica (VRCA) shares does the insider own after the reported transaction?

Following the reported transaction on 11/25/2025, the Interim CFO beneficially owns 8,962 shares of Verrica Pharmaceuticals common stock directly.

What Series C warrants were reported in this Verrica (VRCA) Form 4 filing?

The filing reports 884 Series C warrants with an exercise price of $6.315 per share, exercisable immediately and expiring on 11/25/2030, each linked to Verrica common stock.

How are the Series C warrants structured for Verrica (VRCA)?

Each investment unit purchased includes one share of common stock and a Series C warrant for one fourth of a share of common stock, and the reported 884 Series C warrants are included within the 3,536 investment units.

Is there a beneficial ownership limitation on the Verrica (VRCA) Series C warrants?

Yes. The Series C warrants provide that the holder cannot exercise any portion that would cause their aggregate beneficial ownership to exceed 9.99% of Verrica’s outstanding common stock immediately after the exercise.

Did Verrica (VRCA) adjust share numbers for a reverse stock split in this filing?

Yes. All reported security amounts have been adjusted to reflect a 1-for-10 reverse stock split of Verrica’s common stock that became effective on July 24, 2025.